BioMarin Pharmaceuticals
BMRN
BMRN
438 hedge funds and large institutions have $15.8B invested in BioMarin Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 150 increasing their positions, 145 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
438
Holders Change
+27
Holders Change %
+6.57%
% of All Funds
9.95%
Holding in Top 10
12
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+33.33%
% of All Funds
0.27%
New
78
Increased
150
Reduced
145
Closed
44
Calls
$208M
Puts
$155M
Net Calls
+$52.8M
Net Calls Change
+$34.5M
Top Buyers
| 1 |
BBA
Baker Bros. Advisors
New York
|
$676M |
| 2 |
BlackRock
New York
|
$1.14B |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
$156M |
| 4 |
Citadel Advisors
Miami,
Florida
|
$206M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
$1.92B |
Top Sellers
| 1 |
IG
Ithaka Group
Arlington,
Virginia
|
$5.37M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
$532M |
| 3 |
SIG
Senator Investment Group
New York
|
$0 |
| 4 |
O
OrbiMed
New York
|
$8.97M |
| 5 |
Jennison Associates
New York
|
$1.05B |
